CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04458922
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:57.739095+00:00
- Published At
- 2023-10-23T00:00:00+00:00
- Record Updated At
- 2026-04-13
- Results Posted At
- 2023-10-23
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Central Chondrosarcoma, Grade 2", "Central Chondrosarcoma, Grade 3", "Dedifferentiated Chondrosarcoma", "Metastatic Clear Cell Sarcoma of Soft Tissue", "Metastatic Primary Central Chondrosarcoma", "Unresectable Primary Central Chondrosarcoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"- protocolSection.identificationModule.nctId
"NCT04458922"- protocolSection.identificationModule.officialTitle
"A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-10-23"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.